{
    "id": 1650,
    "fullName": "KIT K642E",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIT K642E lies within the tyrosine kinase domain 1 (exon 13) of the Kit protein (PMID: 15990278). K642E results in constitutive phosphorylation of Kit and activation of downstream signaling (PMID: 15990278, PMID: 19802003), as well as transformation of cultured cells (PMID: 11073817).",
            "references": [
                {
                    "id": 679,
                    "pubMedId": 11073817,
                    "title": "Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11073817"
                },
                {
                    "id": 680,
                    "pubMedId": 15990278,
                    "title": "Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15990278"
                },
                {
                    "id": 681,
                    "pubMedId": 19802003,
                    "title": "c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19802003"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "K642E",
    "createDate": "09/09/2014",
    "updateDate": "05/15/2019",
    "referenceTranscriptCoordinates": {
        "id": 136334,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54728055A>G",
        "cDna": "c.1924A>G",
        "protein": "p.K642E",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17560,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor (GIST) cell line and primary GIST patient-derived cells harboring KIT K642E in culture (PMID: 31205508).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11233,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT K642E demonstrating a partial response and a progression free survival of 5.8 months and overall survival of 18.6 months (PMID: 28327988).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8614,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment resulted in partial response in a patient with recurrent vulval melanoma harboring KIT K642E, with reduction of tumor mass by 35% at 12 weeks (PMID: 20372153).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2093,
                "name": "vulvar melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6700,
                    "pubMedId": 20372153,
                    "title": "Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20372153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17532,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited phosphorylation of KIT and downstream signaling, reduced proliferation, and induced cell-cycle arrest in a cultured gastrointestinal stromal tumor (GIST) cell line harboring KIT K642E, and inhibited proliferation of primary GIST cells harboring KIT K642E in culture (PMID: 31205508).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 538,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Stivarga (regorafenib) inhibited proliferation of gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 21170960).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 318,
                    "pubMedId": 21170960,
                    "title": "Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21170960"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6805,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived GIST cell line harboring KIT K642E demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3860,
                    "pubMedId": 25239608,
                    "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25239608"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7785,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 25673643).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 2284,
                "therapyName": "BGJ398 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6494,
                    "pubMedId": 25673643,
                    "title": "FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25673643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1660,
            "profileName": "KIT K642E",
            "profileTreatmentApproaches": [
                {
                    "id": 1488,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT K642E"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136334,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54728055A>G",
            "cDna": "c.1924A>G",
            "protein": "p.K642E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136335,
            "transcript": "XM_017008178",
            "gDna": "chr4:g.54728055A>G",
            "cDna": "c.1924A>G",
            "protein": "p.K642E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}